Trials / Not Yet Recruiting
Not Yet RecruitingNCT07410182
Bupivacaine Liposome Versus Bupivacaine for Ultrasound-Guided Suprascapular Nerve Combined With Axillary Nerve Block in Analgesia After Arthroscopic Shoulder Surgery
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to compare the post-operative analgesic efficacy and safety of liposomal bupivacaine versus plain bupivacaine when both are used for ultrasound-guided combined suprascapular and axillary nerve block in patients undergoing elective arthroscopic shoulder surgery.
Detailed description
Most liposomal bupivacaine data come from ultrasound-guided brachial-plexus blocks; evidence for its safety and efficacy when used specifically for a combined ultrasound-guided suprascapular-plus-axillary block after arthroscopic shoulder surgery is still missing. This trial fills that gap by comparing liposomal bupivacaine with bupivacaine along, aiming to advance multimodal analgesia and enhanced-recovery pathways, cut postoperative pain and stress, and shorten hospital stay.
Conditions
- Arthroscopic Shoulder Surgery
- Ultrasound Guided Nerve Block
- Bupivacaine
- Suprascapular Nerve Block
- Axillary Nerve Block
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Group A（ liposomal bupivacene） | In the experimental group, 15 mL of a mixture containing liposomal bupivacaine plus plain bupivacaine is deposited around each target nerve (20 mL liposomal bupivacene, 266 mg, combined with 10 mL 0.75 % plain bupivacaine, total 30 mL). |
| DRUG | Group B（bupivacene） | The control group receives 15 mL of 0.25 % plain bupivacaine around each nerve. Unlike the clear solution of plain bupivacaine, liposomal bupivacaine has a distinctive milky-white appearance. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2026-02-13
- Last updated
- 2026-02-13
Source: ClinicalTrials.gov record NCT07410182. Inclusion in this directory is not an endorsement.